PortfoliosLab logoPortfoliosLab logo
BIOGY vs. NVZMY
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

BIOGY vs. NVZMY - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Biogaia AB ADR (BIOGY) and Novozymes AS (NVZMY). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, BIOGY achieves a 16.96% return, which is significantly higher than NVZMY's 3.46% return.


BIOGY

1D
0.00%
1M
12.36%
6M
16.96%
YTD
16.96%
1Y
31.96%
3Y*
14.04%
5Y*
-11.01%
10Y*
ALL TIME*
-6.85%

NVZMY

1D
-1.20%
1M
-0.09%
6M
7.36%
YTD
3.46%
1Y
1.53%
3Y*
11.45%
5Y*
-2.05%
10Y*
4.37%
ALL TIME*
-2.31%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Liquidity Comparison


PositionAvg. Volume Value (2W)Avg. Volume Value (1M)Avg. Volume Value (3M)
$199.50$100.76$47.70K
$1.59M$2.04M$2.52M

BIOGY vs. NVZMY - Yearly Performance Comparison


2026 (YTD)202520242023202220212020
BIOGY
Biogaia AB ADR
16.96%17.64%8.00%19.28%-68.47%-12.12%28.87%
NVZMY
Novozymes AS
3.46%14.29%3.97%12.42%-38.46%46.93%4.27%

Correlation

The correlation between BIOGY and NVZMY is -0.01, meaning there was essentially no consistent relationship between their historical price movements. Each responded to its own set of market drivers.


Correlation
Correlation (1Y)
Focuses on recent behavior, but can change the most.

-0.01

Correlation (3Y)
Balances recent behavior with more history.

0.02

Correlation (5Y)
Shows whether the relationship held over a longer period.

-0.00

Correlation (All Time)
Calculated using the full available price history since Feb 19, 2020

0.01

Fundamentals

Market Cap

BIOGY:

$1.25B

NVZMY:

$30.32B

EPS

BIOGY:

SEK 3.42

NVZMY:

€1.28

PE Ratio

BIOGY:

34.29

NVZMY:

44.00

PS Ratio

BIOGY:

7.53

NVZMY:

2.38

PB Ratio

BIOGY:

10.78

NVZMY:

2.41

Total Revenue (TTM)

BIOGY:

SEK 1.58B

NVZMY:

€11.07B

Gross Profit (TTM)

BIOGY:

SEK 1.15B

NVZMY:

€5.79B

EBITDA (TTM)

BIOGY:

SEK 473.37M

NVZMY:

€3.39B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

BIOGY vs. NVZMY — Risk / Return Rank

Compare historical risk-adjusted metric ranks over the past 12 months.

BIOGY
BIOGY Risk / Return Rank: 8585
Overall Rank
BIOGY Sharpe Ratio Rank: 7979
Sharpe Ratio Rank
BIOGY Sortino Ratio Rank: 8585
Sortino Ratio Rank
BIOGY Omega Ratio Rank: 9999
Omega Ratio Rank
BIOGY Calmar Ratio Rank: 8181
Calmar Ratio Rank
BIOGY Martin Ratio Rank: 8282
Martin Ratio Rank

NVZMY
NVZMY Risk / Return Rank: 4444
Overall Rank
NVZMY Sharpe Ratio Rank: 4747
Sharpe Ratio Rank
NVZMY Sortino Ratio Rank: 4040
Sortino Ratio Rank
NVZMY Omega Ratio Rank: 4040
Omega Ratio Rank
NVZMY Calmar Ratio Rank: 4747
Calmar Ratio Rank
NVZMY Martin Ratio Rank: 4747
Martin Ratio Rank
The rank (0–100) uses a weighted average of the Sharpe, Sortino, Omega, Calmar, and Martin percentile ranks for the trailing 12 months. Higher means stronger historical risk-adjusted performance within the peer group.

BIOGY vs. NVZMY - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Biogaia AB ADR (BIOGY) and Novozymes AS (NVZMY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


BIOGYNVZMYDifference
Sharpe ratioReturn per unit of total volatility

+1.09

Sortino ratioReturn per unit of downside risk

+2.08

Omega ratioGain probability vs. loss probability

2.17

1.04

+1.13

Calmar ratioReturn relative to maximum drawdown

2.20

0.09

+2.11

Martin ratioReturn relative to average drawdown

5.87

0.24

+5.63

BIOGY vs. NVZMY - Sharpe Ratio Comparison

The current BIOGY Sharpe Ratio is 1.16, which is higher than the NVZMY Sharpe Ratio of 0.07. The chart below compares the historical Sharpe Ratios of BIOGY and NVZMY, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

BIOGY vs. NVZMY - Drawdown Comparison

The maximum BIOGY drawdown since its inception was -76.56%, smaller than the maximum NVZMY drawdown of -86.29%. Use the drawdown chart below to compare losses from any high point for BIOGY and NVZMY.


Loading charts...

Drawdown Indicators


BIOGYNVZMYDifference

Max Drawdown

Largest peak-to-trough decline

-76.56%

-86.29%

+9.73%

Max Drawdown (1Y)

Largest decline over 1 year

-14.57%

-20.00%

+5.43%

Max Drawdown (3Y)

Largest decline over 3 years

-22.60%

-29.64%

+7.04%

Max Drawdown (5Y)

Largest decline over 5 years

-75.17%

-51.86%

-23.31%

Max Drawdown (10Y)

Largest decline over 10 years

-51.86%

Current Drawdown

Current decline from peak

-52.92%

-55.47%

+2.55%

Average Drawdown

Average peak-to-trough decline

-50.18%

-57.40%

+7.22%

Ulcer Index

Depth and duration of drawdowns from previous peaks

5.46%

7.68%

-2.22%

Volatility

BIOGY vs. NVZMY - Volatility Comparison

Biogaia AB ADR (BIOGY) has a higher volatility of 11.66% compared to Novozymes AS (NVZMY) at 9.53%. This indicates that BIOGY's price experiences larger fluctuations and is considered to be riskier than NVZMY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


BIOGYNVZMYDifference

Volatility (1M)

Calculated over the trailing 1-month period

11.66%

9.53%

+2.13%

Volatility (6M)

Calculated over the trailing 6-month period

12.30%

19.00%

-6.70%

Volatility (1Y)

Calculated over the trailing 1-year period

27.63%

26.50%

+1.13%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

43.50%

28.14%

+15.36%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

48.29%

27.11%

+21.18%

Dividends

BIOGY vs. NVZMY - Dividend Comparison

BIOGY's dividend yield for the trailing twelve months is around 3.50%, more than NVZMY's 1.57% yield.


PositionTTM20252024202320222021202020192018201720162015
BIOGY
Biogaia AB ADR
3.50%6.38%6.34%2.86%9.31%0.73%0.00%0.00%0.00%0.00%0.00%0.00%
NVZMY
Novozymes AS
1.57%1.51%1.03%2.68%1.68%0.69%0.91%1.03%1.10%1.64%0.95%0.60%

Financials

BIOGY vs. NVZMY - Financials Comparison

This section allows you to compare key financial metrics between Biogaia AB ADR and Novozymes AS. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items

BIOGY vs. NVZMY - Profitability Comparison

The chart below illustrates the profitability comparison between Biogaia AB ADR and Novozymes AS over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

BIOGY - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Biogaia AB ADR reported a gross profit of 320.89M and revenue of 440.86M. Therefore, the gross margin over that period was 72.8%.

NVZMY - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Novozymes AS reported a gross profit of 644.63M and revenue of 1.14B. Therefore, the gross margin over that period was 56.7%.

BIOGY - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Biogaia AB ADR reported an operating income of 132.09M and revenue of 440.86M, resulting in an operating margin of 30.0%.

NVZMY - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Novozymes AS reported an operating income of 272.81M and revenue of 1.14B, resulting in an operating margin of 24.0%.

BIOGY - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Biogaia AB ADR reported a net income of 103.16M and revenue of 440.86M, resulting in a net margin of 23.4%.

NVZMY - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Novozymes AS reported a net income of 202.37M and revenue of 1.14B, resulting in a net margin of 17.8%.


Frequently Asked Questions


BIOGY and NVZMY have a correlation of -0.01, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

BIOGY has higher volatility (11.66%) compared to NVZMY (9.53%). In terms of maximum drawdown, BIOGY dropped -76.56% vs NVZMY's -86.29%.

BIOGY currently has the higher Sharpe Ratio (1.16 vs 0.07), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for BIOGY and NVZMY

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer